Literature DB >> 21484797

[DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo.

S Aggarwal1, M W Ndinguri, R Solipuram, N Wakamatsu, R P Hammer, D Ingram, W Hansel.   

Abstract

Pancreatic ductal adenocarcinomas are invariably lethal, and developing effective treatments that have minimal side effects is a challenge. Previous studies from our laboratory have shown that conjugates of cell membrane disrupting lytic peptides and luteinizing hormone releasing hormone (LHRH) target and destroy human prostate and breast cancer cells in xenografts in the nude mouse model (Hansel et al., Mol Cell Endocrinol 2007;260-262:183-9; Hansel et al., Mol Cell Endocrinol 2007;269:26-33), which express LHRH receptors. The objectives of our study were to synthesize a bioconjugate of LHRH analog ([DLys(6)]-LHRH) and a dietary microchemical (curcumin) and test the hypothesis that [DLys(6)]-LHRH-curcumin targets and inhibits pancreatic cancer cell growth in vitro and in vivo. In in vitro studies, we determined by confocal microscopy, flow cytometry analysis and reverse transcriptase-polymerase chain reaction that MIAPaCa-2, Panc-1 and BxPC-3 pancreatic cancer cell lines express LHRH receptors. [DLys(6)]-LHRH-curcumin inhibited cell proliferation of pancreatic cancer cell lines and induced apoptotic cell death (p < 0.05). Apoptosis was induced by cleavage of polyadenosine-5'-diphosphate-ribose-polymerase and caspase-3. The activity of [DLys(6)]-LHRH-curcumin was equal to free curcumin at equimolar concentrations in vitro. Unlike curcumin itself, the [DLys(6)]-LHRH-curcumin conjugate is water soluble which allows its intravenous administration. In two in vivo studies, [DLys(6)]-LHRH-curcumin given intravenously caused a significant (p < 0.01) reduction in tumor weights and volumes, and free curcumin given by gavage at an equal dose failed to cause a significant reduction in tumor weights and volumes in the nude mouse pancreatic cancer model. [DLys(6)]-LHRH-curcumin treatment enhanced apoptosis compared to [DLys(6)]-LHRH and vehicle-treated controls in tumor tissue. In conclusion, [DLys(6)]-LHRH-curcumin may be useful in treating pancreatic cancer.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21484797      PMCID: PMC4049089          DOI: 10.1002/ijc.26132

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

1.  Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis.

Authors:  Ratna B Ray; Amit Raychoudhuri; Robert Steele; Pratibha Nerurkar
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro.

Authors:  Lynn S Adams; Yanjun Zhang; Navindra P Seeram; David Heber; Shiuan Chen
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

3.  Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.

Authors:  Lynn S Adams; Sheryl Phung; Natalie Yee; Navindra P Seeram; Liya Li; Shiuan Chen
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

4.  Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.

Authors:  Shadan Ali; Aamir Ahmad; Sanjeev Banerjee; Subhash Padhye; Kristin Dominiak; Jacqueline M Schaffert; Zhiwei Wang; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

5.  Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.

Authors:  G Srkalovic; A V Schally; J L Wittliff; T G Day; E L Jenison
Journal:  Int J Oncol       Date:  1998-03       Impact factor: 5.650

6.  Growth-inhibitory actions of analogues of Luteinizing Hormone Releasing Hormone on tumor cells.

Authors:  G Emons; O Ortmann; K D Schulz; A V Schally
Journal:  Trends Endocrinol Metab       Date:  1997-11       Impact factor: 12.015

7.  Targeted proapoptotic LHRH-BH3 peptide.

Authors:  Sonia S Dharap; Tamara Minko
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

8.  Novel polymeric prodrug with multivalent components for cancer therapy.

Authors:  Jayant J Khandare; Pooja Chandna; Yang Wang; Vitaly P Pozharov; Tamara Minko
Journal:  J Pharmacol Exp Ther       Date:  2006-02-09       Impact factor: 4.030

9.  Frequent expression of Fas in gonadotropin-releasing hormone receptor-bearing tumors.

Authors:  A Imai; S Horibe; A Takagi; T Ohno; T Tamaya
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1997-07       Impact factor: 2.435

10.  Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2.

Authors:  Christine Syng-Ai; A Leela Kumari; Ashok Khar
Journal:  Mol Cancer Ther       Date:  2004-09       Impact factor: 6.261

View more
  13 in total

1.  DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment.

Authors:  Fernanda Faião-Flores; José Agustín Quincoces Suarez; Paulo Celso Pardi; Durvanei Augusto Maria
Journal:  Tumour Biol       Date:  2011-12-23

2.  An extract of Artemisia dracunculus L. stimulates insulin secretion from β cells, activates AMPK and suppresses inflammation.

Authors:  Sita Aggarwal; Giri Shailendra; David M Ribnicky; David Burk; Namrata Karki; M S Qingxia Wang
Journal:  J Ethnopharmacol       Date:  2015-05-14       Impact factor: 4.360

Review 3.  Bringing Curcumin to the Clinic in Cancer Prevention: a Review of Strategies to Enhance Bioavailability and Efficacy.

Authors:  Rama I Mahran; Magda M Hagras; Duxin Sun; Dean E Brenner
Journal:  AAPS J       Date:  2016-10-25       Impact factor: 4.009

4.  The curcumin analog DM-1 induces apoptotic cell death in melanoma.

Authors:  Fernanda Faião-Flores; José Agustín Quincoces Suarez; Silvya Stuchi Maria-Engler; Vanessa Soto-Cerrato; Ricardo Pérez-Tomás; Durvanei Augusto Maria
Journal:  Tumour Biol       Date:  2013-01-29

Review 5.  Perspectives on new synthetic curcumin analogs and their potential anticancer properties.

Authors:  Alok Vyas; Prasad Dandawate; Subhash Padhye; Aamir Ahmad; Fazlul Sarkar
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 6.  New perspectives of curcumin in cancer prevention.

Authors:  Wungki Park; A R M Ruhul Amin; Zhuo Georgia Chen; Dong M Shin
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-06

Review 7.  Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.

Authors:  Yosi Gilad; Michael Firer; Gary Gellerman
Journal:  Biomedicines       Date:  2016-05-26

8.  Probing the GnRH receptor agonist binding site identifies methylated triptorelin as a new anti-proliferative agent.

Authors:  Kevin Morgan; Samuel P Leighton; Robert P Millar
Journal:  J Mol Biochem       Date:  2012-06-16

Review 9.  Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice.

Authors:  Sahdeo Prasad; Amit K Tyagi; Bharat B Aggarwal
Journal:  Cancer Res Treat       Date:  2014-01-15       Impact factor: 4.679

10.  A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer.

Authors:  Shengsheng Zhu; Qinxia Wang; Juan Jiang; Yongwei Luo; Zuyue Sun
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.